Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Dec 20;117 Suppl 12A(12):41S-48S.
doi: 10.1016/j.amjmed.2004.10.021.

Interventions to prevent chronic obstructive pulmonary disease exacerbations

Dennis E Niewoehner  1
Affiliations
Review

Interventions to prevent chronic obstructive pulmonary disease exacerbations

Dennis E Niewoehner. Am J Med. .

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) have a profound effect on the patient's health status and decline in lung function; they also impose a significant burden on healthcare resource utilization. Prevention and treatment of exacerbations is listed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) as among the major objectives of COPD management, and it is therefore an important outcome measure when studying any new agent. This article discusses pharmacologic therapy and other measures for preventing exacerbations and hospitalizations due to exacerbations of COPD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier estimates of the probability of no chronic obstructive pulmonary disease exacerbation for the tiotropium and ipratropium treatment groups. (Reproduced with permission from Eur Respir J.62)
Figure 2
Figure 2
Kaplan-Meier estimates of the probability of no chronic obstructive pulmonary disease–related hospitalization for the tiotropium and ipratropium treatment groups. (Reproduced with permission from Eur Respir J.62)
Figure 3
Figure 3
Mean number of chronic obstructive pulmonary disease exacerbations for the tiotropium, salmeterol, and placebo treatment groups. (Reproduced with permission from Thorax.64)
See this image and copyright information in PMC

References

    1. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196–204. - PubMed
    1. Seemungal T.A., Donaldson G.C., Bhowmik A., Jeffries D.J., Wedzicha J.A. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613. - PubMed
    1. Monso E., Ruiz J., Rosell A. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995;152(Pt 1):1316–1320. - PubMed
    1. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest. 1998;113:1542–1548. - PubMed
    1. Rohde G., Wiethege A., Borg I. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax. 2003;58:37–42. - PMC - PubMed

MeSH terms

Substances